NCT03380780View on ClinicalTrials.gov

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 12, 2018

Primary Completion Date

September 18, 2018

Study Completion Date

September 18, 2018

Conditions

Healthy VolunteersHemophilia A

Interventions

DRUG

Emicizumab

Participants will receive a single 1 milligram per kilogram of body weight (mg/kg) subcutaneous dose of emicizumab on Day 1.

Trial Locations (1)

100083

Peking University Third Hospital, Beijing

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT03380780 - A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese Volunteers | Biotech Hunter | Biotech Hunter